Bionomics CEO to Present at ROTH Conference
March 10, 2014 08:00 ET
|
Bionomics Limited
ADELAIDE, South Australia, March 10, 2014 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO) (ADR:BMICY) CEO and managing director Dr Deborah Rathjen will present a company update at the renowned 26th...
BNC105 Phase I/II Trial Achieves a High Response Rate in Ovarian Cancer
February 03, 2014 07:30 ET
|
Bionomics Limited
10 out of 15 patients with positive response in Phase I
Recommended Phase II dose level of 12 mg/m2 determined
Results support continued development in the ovarian cancer...
Bionomics to Present Cancer Compounds at AACR International Conference
October 18, 2013 06:30 ET
|
Bionomics Limited
ADELAIDE, South Australia, Oct. 18, 2013 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO) (ADR:BMICY) will present posters on both BNC101 and BNC105 at the American Association for Cancer Research...
Bionomics Signs Option and License Agreement With Merck
July 31, 2013 06:30 ET
|
Bionomics Limited
ADELAIDE, South Australia, July 31, 2013 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO) today announced an agreement with Merck, known as MSD outside the United States and Canada, to discover and...
Bionomics Initiates IND-Enabling Studies With BNC101
July 29, 2013 06:30 ET
|
Bionomics Limited
ADELAIDE, South Australia, July 29, 2013 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO) (ADR:BMICY) announced today that it has initiated IND-enabling pharmacology and toxicology.
"The initiation...
Bionomics Completes Enrolment for BNC105 Phase II Renal Cancer Trial
June 10, 2013 20:54 ET
|
Bionomics Limited
Phase II trial key milestone in advancing program to partnership
BNC105's innovative approach targets significant market
135 patients enrolled across US, Australia and Singapore...
Manufacture of BNC101 Commences at Lonza
April 23, 2013 06:30 ET
|
Bionomics Limited
ADELAIDE, South Australia, April 23, 2013 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO) (ADR:BMICY) announced today that it has initiated manufacturing activities for BNC101, its lead anti-cancer...
Bionomics Announces Underwritten Rights Issue to Raise $16.4 Million
March 04, 2013 06:30 ET
|
Bionomics Limited
Highlights:
Fully underwritten 1 for 8 non-renounceable rights issue at $0.36 to raise $16.4m
Funds used to advance key development programs, including BNC101 & BNC375
Provides a...
Bionomics Provides BNC101 Update at US Cancer Stem Cell Conference
February 11, 2013 06:00 ET
|
Bionomics Limited
ADELAIDE, Australia, Feb. 11, 2013 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO) (ADR:BMICY) Vice-President of US Operations and Cancer Biology, Dr Peter Chu, will provide an update on the BNC101...
BNC375 Alzheimer's Disease Drug Candidate Presented at Neuroscience Conference
February 04, 2013 06:30 ET
|
Bionomics Limited
BNC375 enhances episodic and working memory
Performance matches Donepezil (US$2.5 billion sales in 2011) in animal tests
ADELAIDE, South Australia, Feb. 4, 2013 (GLOBE NEWSWIRE) --...